1
|
Ksienski D, Truong PT, Wai ES, Croteau NS, Chan A, Patterson T, Clarkson M, Hackett S, Irons S, Lesperance M. Survival Outcomes Following Discontinuation of Ipilimumab and Nivolumab for Advanced Melanoma in a Population-based Cohort. Clin Oncol (R Coll Radiol) 2021; 33:e561-e569. [PMID: 34226113 DOI: 10.1016/j.clon.2021.06.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Accepted: 06/14/2021] [Indexed: 11/17/2022]
Abstract
AIMS Induction ipilimumab and nivolumab followed by maintenance nivolumab improve overall survival compared with ipilimumab alone in patients with advanced melanoma, but immune-related adverse events (irAE) occur commonly. The need for induction discontinuation because of irAE and the relationship between irAE and survival in non-trials patients are unclear. MATERIALS AND METHODS Patients with unresectable stage III-IV melanoma receiving first-line combination immunotherapy at one of six centres between December 2017 and February 2020 outside of trials were identified retrospectively. Landmark 12-week Kaplan-Meier analyses and log-rank tests were used to evaluate associations between discontinuation of induction therapy on overall survival and time to treatment failure (TTF). Multivariable analysis of factors influencing overall survival and TTF was undertaken. RESULTS Among 95 patients, the median age was 62 years, 38.9% had Eastern Cooperative Oncology Group performance status ≥1 and 22.1% had brain metastases. The median follow-up for the whole cohort was 19.8 months by the reverse Kaplan-Meier method. Any grade and grade 3-4 irAE were noted in 78.9% and 44.2% of the cohort, respectively. 44.2% of patients completed induction immunotherapy, whereas 41.1% did not due to irAE. Twelve-week landmark overall survival and TTF were similar in patients who completed induction versus those who did not due to irAE. On multivariable analysis, any grade irAE (versus none) was associated with longer overall survival (hazard ratio = 0.35, 95% confidence interval 0.15-0.82, P = 0.02) and TTF (hazard ratio = 0.38, 95% confidence interval = 0.17-0.81, P = 0.01). Grade 3-4 irAE correlated with longer TTF (hazard ratio = 0.45, 95% confidence interval = 0.20-1.01, P = 0.05). CONCLUSION In this population-based cohort, discontinuation of induction immunotherapy as a result of irAE did not adversely affect overall survival or TTF. irAE observed during ipilimumab and nivolumab induction were associated with improved survival outcomes.
Collapse
Affiliation(s)
- D Ksienski
- BC Cancer-Victoria, British Columbia, Canada; University of British Columbia, British Columbia, Canada.
| | - P T Truong
- BC Cancer-Victoria, British Columbia, Canada; University of British Columbia, British Columbia, Canada
| | - E S Wai
- BC Cancer-Victoria, British Columbia, Canada; University of British Columbia, British Columbia, Canada
| | - N S Croteau
- Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, British Columbia, Canada
| | - A Chan
- University of British Columbia, British Columbia, Canada; BC Cancer-Surrey, British Columbia, Canada
| | - T Patterson
- BC Cancer-Victoria, British Columbia, Canada
| | - M Clarkson
- BC Cancer-Victoria, British Columbia, Canada
| | - S Hackett
- BC Cancer-Victoria, British Columbia, Canada
| | - S Irons
- BC Cancer-Victoria, British Columbia, Canada
| | - M Lesperance
- Department of Mathematics and Statistics, University of Victoria, British Columbia, Canada
| |
Collapse
|
2
|
Freeman AT, Lesperance M, Wai ES, Croteau NS, Fiorino L, Geller G, Brooks EG, Poonja Z, Fenton D, Irons S, Ksienski D. Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab. ACTA ACUST UNITED AC 2020; 27:76-82. [PMID: 32489249 DOI: 10.3747/co.27.5495] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Background Although PD-1 antibodies (PD1 Ab) are the standard of care for advanced non-small-cell lung cancer (ansclc), most patients will progress. We compared survival outcomes for patients with ansclc who received systemic therapy (st) after progression and for those who did not. Additionally, clinical characteristics that predicted receipt of st after PD1 Ab failure were evaluated. Methods All patients with ansclc in British Columbia initiated on nivolumab or pembrolizumab between June 2015 and November 2017, with subsequent progression, were identified. Eligibility criteria for additional st included an Eastern Cooperative Oncology Group (ecog) performance status (ps) of 3 or less and survival for more than 30 days from the last PD1 Ab treatment. Post-progression survival (pps) was assessed by landmark analysis. Baseline characteristics associated with pps were identified by multivariable analysis. Results Of 94 patients meeting the eligibility criteria, 33 received st after progression. In 75.6%, a PD1 Ab was received as first- or second-line treatment. The most common sts were erlotinib (36.4%) and docetaxel (27.3%). No statistically significant difference in median pps was observed between patients who did and did not receive st within 30 days of their last PD1 Ab treatment (6.9 months vs. 3.6 months, log-rank p = 0.15.) In multivariable analysis, factors associated with increased pps included an ecog ps of 0 or 1 compared with 2 or 3 [hazard ratio (hr): 0.42; 95% confidence interval (ci): 0.24 to 0.73; p = 0.002] and any response compared with no response to PD1 Ab (hr: 0.54; 95% ci: 0.33 to 0.90; p = 0.02). Conclusions In this cohort, only 35.1% of patients eligible for post-PD1 Ab therapy received st. Post-progression survival was not significantly affected by receipt of post-progression therapy. Prospective trials are needed to clarify the benefit of post-PD1 Ab treatments.
Collapse
Affiliation(s)
| | - M Lesperance
- University of Victoria, Department of Mathematics and Statistics, Victoria, BC
| | - E S Wai
- BC Cancer-Victoria, Victoria, BC.,University of British Columbia, Department of Medicine, Vancouver, BC
| | - N S Croteau
- University of Victoria, Department of Mathematics and Statistics, Victoria, BC
| | - L Fiorino
- BC Cancer-Victoria, Victoria, BC.,University of British Columbia, Department of Medicine, Vancouver, BC
| | - G Geller
- BC Cancer-Victoria, Victoria, BC.,University of British Columbia, Department of Medicine, Vancouver, BC
| | - E G Brooks
- BC Cancer-Victoria, Victoria, BC.,University of British Columbia, Department of Medicine, Vancouver, BC
| | - Z Poonja
- BC Cancer-Victoria, Victoria, BC.,University of British Columbia, Department of Medicine, Vancouver, BC
| | - D Fenton
- BC Cancer-Victoria, Victoria, BC.,University of British Columbia, Department of Medicine, Vancouver, BC
| | - S Irons
- University of Victoria, Department of Mathematics and Statistics, Victoria, BC
| | - D Ksienski
- BC Cancer-Victoria, Victoria, BC.,University of British Columbia, Department of Medicine, Vancouver, BC
| |
Collapse
|
3
|
Ksienski D, Wai E, Croteau N, Freeman A, Fiorino L, Chan A, Fenton D, Geller G, Brooks E, Poonja Z, Irons S, Lesperance M. MA07.11 Survival Outcomes Based on Gender of Advanced Nonsmall Cell Lung Cancer Patients Treated with Pembrolizumab or Nivolumab in Everyday Clinical Practice. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
4
|
Ksienski D, Wai E, Lesperance M, Croteau N, Fiorino L, Poonja Z, Geller G, Fenton D, Brooks E, Glick D. P1.01-50 Real World Experience of Nivolumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Ksienski D, Wai E, Lesperance M, Croteau N, Fiorino L, Poonja Z, Fenton D, Geller G, Brooks E, Glick D. P1.01-51 Real world Experience of Pembrolizumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
Glick D, Wai E, Lesperance M, Croteau N, Brooks E, Fenton D, Fiorino L, Geller G, Poonja Z, Ksienski D. P1.01-24 Clinical Efficacy of Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients Treated with Prior Radiotherapy. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
7
|
Tyler S, Truong P, Lesperance M, Nichol A, Baliski C, Warburton R, Tyldesley S. Effect of Margin Status on 10-Year Local Recurrence and Survival Outcomes in a Large Population-Based Analysis of Women Treated With Breast-Conserving Therapy. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Tyler S, Truong P, Lesperance M, Nichol A, Baliski C, Warburton R, Tyldesley S. Abstract P1-11-01: The effect of close and positive surgical margins on 10-year local recurrence and survival outcomes in women treated with breast conserving surgery plus adjuvant radiotherapy. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-11-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- S Tyler
- British Columbia Cancer Agency, Victoria and Vancouver, BC, Canada; University of Victoria, Victoria, BC, Canada
| | - P Truong
- British Columbia Cancer Agency, Victoria and Vancouver, BC, Canada; University of Victoria, Victoria, BC, Canada
| | - M Lesperance
- British Columbia Cancer Agency, Victoria and Vancouver, BC, Canada; University of Victoria, Victoria, BC, Canada
| | - A Nichol
- British Columbia Cancer Agency, Victoria and Vancouver, BC, Canada; University of Victoria, Victoria, BC, Canada
| | - C Baliski
- British Columbia Cancer Agency, Victoria and Vancouver, BC, Canada; University of Victoria, Victoria, BC, Canada
| | - R Warburton
- British Columbia Cancer Agency, Victoria and Vancouver, BC, Canada; University of Victoria, Victoria, BC, Canada
| | - S Tyldesley
- British Columbia Cancer Agency, Victoria and Vancouver, BC, Canada; University of Victoria, Victoria, BC, Canada
| |
Collapse
|
9
|
Lesperance M, Reed WJ, Stephens MA, Tsao C, Wilton B. Assessing Conformance with Benford's Law: Goodness-Of-Fit Tests and Simultaneous Confidence Intervals. PLoS One 2016; 11:e0151235. [PMID: 27018999 PMCID: PMC4809611 DOI: 10.1371/journal.pone.0151235] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2015] [Accepted: 02/25/2016] [Indexed: 11/22/2022] Open
Abstract
Benford’s Law is a probability distribution for the first significant digits of numbers, for example, the first significant digits of the numbers 871 and 0.22 are 8 and 2 respectively. The law is particularly remarkable because many types of data are considered to be consistent with Benford’s Law and scientists and investigators have applied it in diverse areas, for example, diagnostic tests for mathematical models in Biology, Genomics, Neuroscience, image analysis and fraud detection. In this article we present and compare statistically sound methods for assessing conformance of data with Benford’s Law, including discrete versions of Cramér-von Mises (CvM) statistical tests and simultaneous confidence intervals. We demonstrate that the common use of many binomial confidence intervals leads to rejection of Benford too often for truly Benford data. Based on our investigation, we recommend that the CvM statistic Ud2, Pearson’s chi-square statistic and 100(1 − α)% Goodman’s simultaneous confidence intervals be computed when assessing conformance with Benford’s Law. Visual inspection of the data with simultaneous confidence intervals is useful for understanding departures from Benford and the influence of sample size.
Collapse
Affiliation(s)
- M. Lesperance
- Department of Mathematics and Statistics, University of Victoria, Victoria, Canada
- * E-mail:
| | - W. J. Reed
- Department of Mathematics and Statistics, University of Victoria, Victoria, Canada
| | | | - C. Tsao
- Department of Mathematics and Statistics, University of Victoria, Victoria, Canada
| | | |
Collapse
|
10
|
Wood VM, Christenson JM, Innes GD, Lesperance M, McKnight D. The NARC (Nonsteroidal Anti-inflammatory in Renal Colic) Trial. Single-dose intravenous ketorolac versus titrated intravenous meperidine in acute renal colic: a randomized clinical trial. CAN J EMERG MED 2015; 2:83-9. [PMID: 17637129 DOI: 10.1017/s1481803500004656] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
ABSTRACTObjectives:Intravenous (IV) opioid titration is an accepted method of relieving acute renal colic. Studies have shown that nonsteroidal anti-inflammatory drugs (NSAIDs) are also effective in this setting. Our objective was to compare single-dose ketorolac and titrated meperidine, both administered intravenously, with respect to speed and degree of analgesia, adverse effects and functional status. Our primary hypothesis was that these agents provide equivalent analgesia within 60 minutes. Our secondary hypotheses were that ketorolac-treated patients would experience fewer adverse effects and would be better able to resume usual activity.Methods:This was a multicentre, double-blind randomized equivalence trial in a convenience sample of patients age 18–65 with moderate or severe renal colic, documented by intravenous pyelogram, ultrasound or stone passage. Meperidine-treated patients received 50 mg IV meperidine at 0 minutes, then 25–50 mg every 15 minutes as needed for ongoing pain. Ketorolac-treated patients received 30 mg IV ketorolac at 0 minutes and placebo injections every 15 minutes as needed. Pain levels and adverse effects were assessed every 15 minutes, and functional status was evaluated at 60 minutes. Our primary outcome was the proportion of patients with mild or no pain at 60 minutes.Results:Overall, 49 of 77 meperidine-treated patients (64%; 95% confidence interval [CI], 53%–75%) and 47 of 65 ketorolac-treated patients (72%; 95% CI, 61%–83%) achieved successful pain relief at 60 minutes (pvalue for equivalence = 0.002). Ten percent of meperidine-treated patients and 44% of ketorolac-treated patients were able to resume usual activity at 60 minutes (p= 0.001).Conclusions:In the doses studied, single-dose IV ketorolac is as effective as titrated IV meperidine for the relief of acute renal colic and causes less functional impairment.
Collapse
Affiliation(s)
- V M Wood
- Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada.
| | | | | | | | | |
Collapse
|
11
|
Lesperance M, Martinov M, Thomson RM. Monte Carlo dosimetry for 103Pd, 125I, and 131Cs ocular brachytherapy with various plaque models using an eye phantom. Med Phys 2014; 41:031706. [PMID: 24593710 DOI: 10.1118/1.4864474] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
PURPOSE To investigate dosimetry for ocular brachytherapy for a range of eye plaque models containing(103)Pd, (125)I, or (131)Cs seeds with model-based dose calculations. METHODS Five representative plaque models are developed based on a literature review and are compared to the standardized COMS plaque, including plaques consisting of a stainless steel backing and acrylic insert, and gold alloy backings with: short collimating lips and acrylic insert, no lips and silicone polymer insert, no lips and a thin acrylic layer, and individual collimating slots for each seed within the backing and no insert. Monte Carlo simulations are performed using the EGSnrc user-code BrachyDose for single and multiple seed configurations for the plaques in water and within an eye model (including nonwater media). Simulations under TG-43 assumptions are also performed, i.e., with the same seed configurations in water, neglecting interseed and plaque effects. Maximum and average doses to ocular structures as well as isodose contours are compared for simulations of each radionuclide within the plaque models. RESULTS The presence of the plaque affects the dose distribution substantially along the plaque axis for both single seed and multiseed simulations of each plaque design in water. Of all the plaque models, the COMS plaque generally has the largest effect on the dose distribution in water along the plaque axis. Differences between doses for single and multiple seed configurations vary between plaque models and radionuclides. Collimation is most substantial for the plaque with individual collimating slots. For plaques in the full eye model, average dose in the tumor region differs from those for the TG-43 simulations by up to 10% for(125)I and (131)Cs, and up to 17% for (103)Pd, and in the lens region by up to 29% for (125)I, 34% for (103)Pd, and 28% for (131)Cs. For the same prescription dose to the tumor apex, the lowest doses to critical ocular structures are generally delivered with plaques containing (103)Pd seeds. CONCLUSIONS The combined effects of ocular and plaque media on dose are significant and vary with plaque model and radionuclide, suggesting the importance of model-based dose calculations employing accurate ocular and plaque media and geometries for eye plaque brachytherapy.
Collapse
Affiliation(s)
- Marielle Lesperance
- Carleton Laboratory for Radiotherapy Physics, Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - M Martinov
- Carleton Laboratory for Radiotherapy Physics, Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| | - R M Thomson
- Carleton Laboratory for Radiotherapy Physics, Department of Physics, Carleton University, Ottawa, Ontario K1S 5B6, Canada
| |
Collapse
|
12
|
Lesperance M, Inglis-Whalen M, Thomson RM. Model-based dose calculations for COMS eye plaque brachytherapy using an anatomically realistic eye phantom. Med Phys 2014; 41:021717. [PMID: 24506608 DOI: 10.1118/1.4861715] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
PURPOSE To investigate the effects of the composition and geometry of ocular media and tissues surrounding the eye on dose distributions for COMS eye plaque brachytherapy with(125)I, (103)Pd, or (131)Cs seeds, and to investigate doses to ocular structures. METHODS An anatomically and compositionally realistic voxelized eye model with a medial tumor is developed based on a literature review. Mass energy absorption and attenuation coefficients for ocular media are calculated. Radiation transport and dose deposition are simulated using the EGSnrc Monte Carlo user-code BrachyDose for a fully loaded COMS eye plaque within a water phantom and our full eye model for the three radionuclides. A TG-43 simulation with the same seed configuration in a water phantom neglecting the plaque and interseed effects is also performed. The impact on dose distributions of varying tumor position, as well as tumor and surrounding tissue media is investigated. Each simulation and radionuclide is compared using isodose contours, dose volume histograms for the lens and tumor, maximum, minimum, and average doses to structures of interest, and doses to voxels of interest within the eye. RESULTS Mass energy absorption and attenuation coefficients of the ocular media differ from those of water by as much as 12% within the 20-30 keV photon energy range. For all radionuclides studied, average doses to the tumor and lens regions in the full eye model differ from those for the plaque in water by 8%-10% and 13%-14%, respectively; the average doses to the tumor and lens regions differ between the full eye model and the TG-43 simulation by 2%-17% and 29%-34%, respectively. Replacing the surrounding tissues in the eye model with water increases the maximum and average doses to the lens by 2% and 3%, respectively. Substituting the tumor medium in the eye model for water, soft tissue, or an alternate melanoma composition affects tumor dose compared to the default eye model simulation by up to 16%. In the full eye model simulations, the average dose to the lens is larger by 7%-9% than the dose to the center of the lens, and the maximum dose to the optic nerve is 17%-22% higher than the dose to the optic disk for all radionuclides. In general, when normalized to the same prescription dose at the tumor apex, doses delivered to all structures of interest in the full eye model are lowest for(103)Pd and highest for (131)Cs, except for the tumor where the average dose is highest for (103)Pd and lowest for (131)Cs. CONCLUSIONS The eye is not radiologically water-equivalent, as doses from simulations of the plaque in the full eye model differ considerably from doses for the plaque in a water phantom and from simulated TG-43 calculated doses. This demonstrates the importance of model-based dose calculations for eye plaque brachytherapy, for which accurate elemental compositions of ocular media are necessary.
Collapse
Affiliation(s)
- Marielle Lesperance
- Carleton Laboratory for Radiotherapy Physics, Department of Physics, Carleton University, Ottawa K1S 5B6, Canada
| | - M Inglis-Whalen
- Carleton Laboratory for Radiotherapy Physics, Department of Physics, Carleton University, Ottawa K1S 5B6, Canada
| | - R M Thomson
- Carleton Laboratory for Radiotherapy Physics, Department of Physics, Carleton University, Ottawa K1S 5B6, Canada
| |
Collapse
|
13
|
Lesperance M, Martinov M, Inglis-Whalen M, Thomson R. WE-C-108-10: Model-Based Dose Calculations for Eye Plaque Brachytherapy. Med Phys 2013. [DOI: 10.1118/1.4815533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
14
|
Karam I, Lesperance M, Tyldesley S, Speers C, Lesperance M, Truong P. Treatment Patterns and Locoregional Recurrence Outcomes in Patients with pN0(i+) Breast Cancer. Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
15
|
Nguyen D, Truong P, Alexander C, Walter C, Hayashi E, Christie J, Lesperance M. Can Locoregional Treatment of the Primary Tumor Improve Outcomes for Women with Stage IV Breast Cancer at Diagnosis? Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
16
|
Nguyen DHA, Truong PT, Lesperance M, Alexander C, Walter CV, Hayashi E, Christie J, Olivotto IA. Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis? J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.89] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
89 Background: To determine whether locoregional treatment (LRT) of the primary tumor improves outcomes in patients with stage IV breast cancer at diagnosis. Methods: The study cohort comprised 733 women referred from 1996 to 2005 to a population-based cancer institution with clinical or pathologic M1 breast cancer at diagnosis. Patient, tumor, and treatment characteristics were compared between women who were treated with (n=378) and without LRT (n=355) of the primary tumor. Five-year Kaplan-Meier overall survival (OS) and locoregional progression-free survival (LRPFS) were compared between groups. Multivariable analysis to control for potential confounding factors was performed using Cox regression modeling. Results: LRT consisted of surgery alone in 67%, radiotherapy alone in 22%, and both in 11% of patients. LRT use was significantly associated with age <50 years, ECOG performance status 0-1, T1-2 tumors, and N0-1 disease, (all p<0.05). Subjects with less metastatic disease burden and those asymptomatic from the M1 disease were more likely to undergo LRT (p<0.001). Systemic therapy was used in 92% and 85% of patients treated with vs. without LRT, respectively. Five-year OS rates in the LRT and no LRT cohorts were 21% vs 14% (p<0.001). The 5-year LRPFS rates were 72% vs 46% (p<0.001). Among 378 patients who underwent LRT, 5-year OS rates were higher in patients with age <50, ECOG 0-1, ER positive disease, clear surgical margins, single M1 subsite, bone only metastases, and 1-3 metastatic lesions (all p<0.003). Type of LRT (surgery vs radiotherapy vs both) and type of surgery (lumpectomy vs mastectomy) were not associated with 5-year OS (all p>0.05). On multivariable analysis, LRT was associated with improved OS (hazard ratio 0.78, 95% confidence interval 0.64-0.94, p=0.009). Conclusions: LRT of the primary disease was associated with improved survival in women with stage IV breast cancer at diagnosis. Among subjects treated with LRT, the most favorable survival rates were observed in patients with young age, good performance status, ER-positive disease, clear resection margins and in those with distant disease limited to one subsite, bone only, or fewer than 4 metastatic lesions.
Collapse
Affiliation(s)
- D. H. A. Nguyen
- British Columbia Cancer Agency, Victoria, BC, Canada; University of Victoria, Victoria, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada
| | - P. T. Truong
- British Columbia Cancer Agency, Victoria, BC, Canada; University of Victoria, Victoria, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada
| | - M. Lesperance
- British Columbia Cancer Agency, Victoria, BC, Canada; University of Victoria, Victoria, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada
| | - C. Alexander
- British Columbia Cancer Agency, Victoria, BC, Canada; University of Victoria, Victoria, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada
| | - C. V. Walter
- British Columbia Cancer Agency, Victoria, BC, Canada; University of Victoria, Victoria, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada
| | - E. Hayashi
- British Columbia Cancer Agency, Victoria, BC, Canada; University of Victoria, Victoria, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada
| | - J. Christie
- British Columbia Cancer Agency, Victoria, BC, Canada; University of Victoria, Victoria, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada
| | - I. A. Olivotto
- British Columbia Cancer Agency, Victoria, BC, Canada; University of Victoria, Victoria, BC, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada
| |
Collapse
|
17
|
Dyar SH, Lesperance M, Shannon RP, Sloan JA, Colon-Otero G. Effect of a nurse practitioner (ARNP)–directed intervention on the quality of life of patients with metastatic cancer: Results of a randomized pilot study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.9097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Lesperance M, Smerdon JE, Beltrami H. Propagation of linear surface air temperature trends into the terrestrial subsurface. ACTA ACUST UNITED AC 2010. [DOI: 10.1029/2010jd014377] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
19
|
Panet-Raymond V, Truong P, Alexander C, Lesperance M, McDonald R, Ross L, Ryhorchuk A, Watson P. Pathological Factors of the Recurrent Tumor Predict Outcome in Patients with Ipsilateral Breast Tumor Recurrences. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
20
|
Truong P, Lupe K, Alexander C, Lesperance M, Tyldesley S. Subsets of Women with Close or Positive Margins after Breast Conserving Surgery with High Local Recurrence Risk Despite Breast Plus Boost Radiotherapy. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.157] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
21
|
Truong P, Liz K, Lesperance M, Chia S, Macfarlane R, Speers C, Olivotto I. 56 Micrometastatic node-positive breast cancer: An analysis of outcomes in comparison to node-negative and macrometastatic node-positive disease. Radiother Oncol 2006. [DOI: 10.1016/s0167-8140(06)80797-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
22
|
Webber A, Virji-Babul N, Edwards R, Lesperance M. Stiffness and postural stability in adults with Down syndrome. Exp Brain Res 2004; 155:450-8. [PMID: 14762637 DOI: 10.1007/s00221-003-1743-7] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2003] [Accepted: 09/16/2003] [Indexed: 12/01/2022]
Abstract
The purpose of this study was to characterize postural sway in quiet standing under eyes-open and eyes-closed conditions, and to obtain a measure of postural stiffness during quiet standing in adults with Down syndrome (DS) versus control subjects. We obtained descriptive measures from centre-of-pressure (COP) data and analysed and compared COP trajectories and postural stiffness estimates from two stochastic models, the "pinned polymer" (PP) and "inverted pendulum" (IP) models. These estimates were correlated with clinical measures of muscle tone. Our results showed that overall, estimated values for postural stiffness from both models were larger for the DS group than for normal controls. In addition, average stiffness measures were greater under the eyes-closed condition than under the eyes-open condition for the DS group. The IP model detected significant trends over trials whereas the PP model did not. Clinical assessment of muscle tone for the DS group ranged from low to high-normal and there was no significant correlation with the postural stiffness measures obtained from either model. These results suggest that individuals with DS have the ability to modulate their underlying "stiffness" under conditions of quiet standing. Furthermore, there appears to be no strong relationship between clinical measures of muscle tone and postural stiffness measures under dynamic conditions.
Collapse
Affiliation(s)
- A Webber
- Department of Mathematics and Statistics, University of Victoria, PO Box 3045, Stn CSC, BC V8W 3P4, Victoria, Canada
| | | | | | | |
Collapse
|
23
|
Brigden ML, Graydon C, McLeod B, Lesperance M. Prothrombin time determination. The lack of need for a discard tube and 24-hour stability. Am J Clin Pathol 1997; 108:422-6. [PMID: 9322596 DOI: 10.1093/ajcp/108.4.422] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The National Committee for Clinical Laboratory Standards (NCCLS) recommends that all coagulation studies be done on a specimen from the tube drawn second or later. For patients receiving long-term anticoagulant therapy, this may require that the first tube of blood drawn be discarded for each prothrombin evaluation. In a prospective study we compared the prothrombin times (PTs) as international normalized ratios (INRs) from a series of three tubes obtained from 241 patients receiving consistent dosages of oral anticoagulant therapy to determine the need for discarding the first tube drawn, as well as the stability of PT determinations over a 24-hour period. Tube one was treated as the discard tube. Tubes one and two were analyzed within the laboratory's standard 4-hour time frame, while tube three was kept stoppered at room temperature, centrifuged a half hour before PT determination, and analyzed after a 24-hour delay. Comparisons of the INRs were made in four ranges comprising 1.2 to 2.0, 2.1 to 3.5, 3.6 to 5.9, and 6.0 or more. Most INR comparisons were less than the 10% maximum variance listed as acceptable by the NCCLS. A comparison of INR results between tube two and tube one showed a statistically significant difference only for the INR range of 6.0 or more. The comparison of the 24-hour specimen with tube one showed statistically significant differences in paired t testing for the first three INR cohorts. However, the 95% confidence intervals demonstrated that these mean differences were probably too small to be clinically significant. For the fourth cohort (INR > or = 6.0) the mean difference was not significantly different on paired t testing, but the 95% confidence interval was larger at -0.07 to 0.839. In this sample of outpatients receiving consistent dosages of oral anticoagulant therapy the use of a discard tube seemed unnecessary, and the 24-hour stability of PT determinations was documented.
Collapse
Affiliation(s)
- M L Brigden
- Penticton Regional Hospital Oncology Clinic, British Columbia, Canada
| | | | | | | |
Collapse
|
24
|
Lesperance M, Baumgartner D, Kauffman CA. Polyarticular arthritis due to Sporothrix schenckii. Mycoses 1988; 31:599-603. [PMID: 3231232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|